Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina ex...
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) announce...
etherna immunotherapies NV (“etherna”), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announc...
Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced no...
Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a completely new production facility in Odense, Denmark. The investment mar...
R-Bridge Healthcare Fund ("R-Bridge"), an affiliate of CBC Group, Asia's largest healthcare-dedicated asset management firm, today announced...
Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, just completed significant expansions in...
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) announced the signing of a definitive agreement for...
TrakCel, a provider of integrated cell and gene therapy (CGT) orchestration solutions for the precise management, control and tracking of CGTs has announce...
Adragos Pharma, a leading Contract Development & Manufacturing Organisation (CDMO), has significantly enhanced its production capabilities with the com...
The Global Health Innovative Technology (GHIT) Fund announced a total investment of approximately JPY 578 million (USD 4.0 million1) in four...
Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) announced that Syndax has entered into a $350 million synth...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, reported its consolidated financial results for the third quarter...
AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic c...
© 2025 Biopharma Boardroom. All Rights Reserved.
